
Funda Meric-Bernstam MD
Surgical Oncology (Other than Breast)
Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy Nellie B. Connally Chair in Breast Cancer Research Professor, Division of Cancer Medicine and Surgery
Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Fax+1 713-745-7296
Dr. Meric-Bernstam is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- University of MichiganResidency, Surgery, 1991 - 1998
- Yale School of MedicineClass of 1991
Certifications & Licensure
- FL State Medical License 2021 - Present
- AZ State Medical License 2023 - 2026
- GA State Medical License 2023 - 2026
- OK State Medical License 2020 - 2026
- TN State Medical License 2023 - 2026
- TX State Medical License 1999 - 2026
- AL State Medical License 2023 - 2025
- American Board of Preventive Medicine Clinical Informatics
- American Board of Surgery Surgery
- Join now to see all
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2012-2014
- Top Doctors:SE Texas Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2011-2013
- Join now to see all
Clinical Trials
- Bevacizumab in Multiple Phase I Combinations Start of enrollment: 2007 Oct 10
- Axillary Reverse Mapping for Invasive Carcinoma of the Breast Start of enrollment: 2008 Mar 01
- Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy Start of enrollment: 2009 Mar 30
- Join now to see all
Publications & Presentations
PubMed
- Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances.Lorenzo Guidi, Julian Etessami, Carmine Valenza, Augusto Valdivia, Funda Meric-Bernstam
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2025-06-01 - 1 citationsSummary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02.Ana Oaknin, Jung-Yun Lee, Vicky Makker, Do-Youn Oh, Susana Banerjee
Advances in Therapy. 2025-05-01 - Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer.Mohamed A Gouda, Amrit Gonugunta, Ecaterina E Dumbrava, Timothy A Yap, Jordi Rodon
Clinical Cancer Research. 2025-04-01
Lectures
- Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.2019 ASCO Annual Meeting - 6/1/2019
- Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Single agent activity of ZW25, a HER's targeted bispecific antibody, in heavily pretreated HERs' expressing cancers.2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
- Join now to see all
Press Mentions
- MD Anderson Unveils Breakthrough Research Findings – February 10, 2025February 10th, 2025
- Novel ADC AZD8205 Demonstrates Manageable Safety Profile and Preliminary Efficacy in First-in-Human TrialSeptember 13th, 2024
- MD Anderson Research Highlights for May 8, 2024May 8th, 2024
- Join now to see all
Grant Support
- Training of Academic Surgical OncologistsUNIVERSITY OF TX MD ANDERSON CAN CTR1994–2028
- A phase II multi-center trial evaluating dual targeting of the PI3K/AKT and NOS pathways for treating metaplastic breast cancer (MpBC)METHODIST HOSPITAL RESEARCH INSTITUTE2022–2027
- Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffoldUNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR2022–2027
- Texas EXperimental Cancer Therapeutics Network - TEX CTNUNIVERSITY OF TX MD ANDERSON CAN CTR2014–2026
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: